ChemicalBook > Product Catalog >Biochemical Engineering >Inhibitors >Velpatasvir

Velpatasvir

Velpatasvir Suppliers list
Company Name: Hangzhou Cheminspire Technology Co., Ltd.  Gold
Tel: 0571-89081561; 10006559855
Email: info@cheminspire.com
Company Name: INTERCHEMIE NANJING PHARMATECH CO., LTD  Gold
Tel: 13656237714 13656237714;
Email: xiaokunfu@kyyykj.com
Company Name: Shanghai jing Hao pharmaceutical technology co., LTD  Gold
Tel: 021-68900963 15618693615
Email: sales@jinghaopharma.com
Company Name: NANJING ZENJI PHARMACEUTICALS  Gold
Tel: 0512-62750571
Email: marketing@zenjipharma.com
Company Name: Linyi Shengyuan Biotechnology Co., LTD  Gold
Tel: 13953971485
Email: 2199605322@qq.com

Velpatasvir manufacturers

  • Velpatasvir
  • Velpatasvir pictures
  • 2026-09-23
  • CAS:1377049-84-7
  • Min. Order: 1g
  • Purity: More Than 99%
  • Supply Ability: 100kg/Month
  • Velpatasvir
  • Velpatasvir pictures
  • 2026-09-23
  • CAS:1377049-84-7
  • Min. Order: 1g
  • Purity: 98%-102%
  • Supply Ability: 10 KGS
  • Velpatasvir
  •  Velpatasvir  pictures
  • 2026-09-01
  • CAS:1377049-84-7
  • Min. Order: 1kg
  • Purity: 99%
  • Supply Ability: 10000kg
Velpatasvir Basic information
Product Name:Velpatasvir
Synonyms:Velpatasvir;velpatasvir(GS-5816);methyl ((2s)-1-((2s,5s)-2-(9-(2-((2s,4s)-1-((2r)-2-((methoxycarbonyl)amino)-2-phenylacetyl)-4-(methoxymethyl)pyrrolidin-2-yl)-1h-imidazol-5-yl)-1,11-dihydroisochromeno(4',3':6,7)naphtho(1,2-d)imidazol-2-yl)-5-methylpyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate;Velpatasvir API;Unifiram (DM-232);Methyl [(2S)-1-[(2S,5S)-2-[9-[2-[(2S,4S)-1-[(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl]-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,11-dihydroisochromeno[4',3':6,7]naphtho[1,2-d]imidazol-2-yl]-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-y;MFCD28411371;Product:Velpatasvir
CAS:1377049-84-7
MF:C49H54N8O8
MW:883
EINECS:1592732-453-0
Product Categories:1377049-84-7
Mol File:1377049-84-7.mol
Velpatasvir Structure
Velpatasvir Chemical Properties
Melting point >170oC (dec.)
density 1.314±0.06 g/cm3(Predicted)
storage temp. -20°C
solubility Soluble in DMSO (>25 mg/ml)
form solid
pka10.75±0.46(Predicted)
color Pale yellow
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months.
InChIKeyFHCUMDQMBHQXKK-CDIODLITSA-N
SMILESC(OC)(=O)N[C@H](C1=CC=CC=C1)C(N1C[C@@H](COC)C[C@H]1C1NC(C2=CC=C3C4C(OCC3=C2)=CC2=C3C(=CC=C2C=4)N=C([C@@H]2CC[C@H](C)N2C(=O)[C@@H](NC(OC)=O)C(C)C)N3)=CN=1)=O
Safety Information
MSDS Information
Velpatasvir Usage And Synthesis
DescriptionVelpatasvir (1377049-84-7) is an extremely potent pan-genotypic hepatitis C virus (HCV) NS5A inhibitor.1 It is a component of Epclusa and Vosevi, two clinically useful medications with 98% and 97%, respectively, cure rates for HCV. It displayed EC50’s for GTs 1-4, 6a ranging from 6-16 pM, GT5a at 75 pM, and GT6e at 130 pM. Velpatasvir also displayed an excellent barrier to viral resistance. It has been shown in silico, that velpatasvir binds to the SARS-CoV-2 spike protein and may be a potential therapeutic.2
UsesVelpatasvir is a NS5A inhibitor in patients with hepatitis C (HCV) infection.
DefinitionChEBI: Velpatasvir is a complex organic heteropentacyclic compound that is a hepatitis C virus nonstructural protein 5A inhibitor used in combination with sofosbuvir (under the brand name Epclusa) for treatment of patients with chronic hepatitis C of all six major genotypes. It has a role as an antiviral drug and a hepatitis C virus nonstructural protein 5A inhibitor. It is an organic heteropentacyclic compound, a N-acylpyrrolidine, a L-valine derivative, a carbamate ester, a member of imidazoles, a ring assembly and an ether.
Brand nameEpclusa, Sofosvel, Velpanat (all in combination with sofosbuvir)
in vivo

Velpatasvir (10 mg/kg/d, p.o.) alone or in combination with Sofosbuvir (HY-15005) (20 mg/kg/d) inhibits liver fibrosis in the CCl4-induced non-HCV rat model[3].

Animal Model:CCl4-induced non-HCV rat model[3]
Dosage:10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d)
Administration:p.o.
Result:Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues.
Inhibited hepatic stellate cells (HSCs).
References[1] JOHN O. LINK . Discovery of velpatasvir (GS-5816): A potent pan-genotypic HCV NS5A inhibitor in the single-tablet regimens Vosevi® and Epclusa®[J]. Bioorganic & Medicinal Chemistry Letters, 2019, 29 16: Pages 2415-2427. DOI:10.1016/j.bmcl.2019.04.027
[2] ONAT KADIOGLU . Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning[J]. Computers in biology and medicine, 2021, 133: Article 104359. DOI:10.1016/j.compbiomed.2021.104359
Velpatasvir Preparation Products And Raw materials
Tag:Velpatasvir(1377049-84-7) Related Product Information
(S)-1-tert-Butyl 5-methyl 2-((tert-butoxycarbonyl)amino)pentanedioate ZANAMIVIR HYDRATE Dutasteride Tacrolimus Zofenopril calcium Sofosbuvir Rituximab Levofloxacin hydrochloride (2S,4S)-1-(tert-butoxycarbonyl)-4-(MethoxyMethyl)pyrrolidine-2-carboxylic acid Velpatasvir intermediate Velpatasvir intermediate Velpatasvir intermediate (R)-2-(methoxycarbonylamino)-2-phenylacetic acid Velpatasvir Co Povidone Velpatasvir intermediate (2S,5S)-1-((methoxycarbonyl)-L-valyl)-5-methylpyrrolidine-2-carboxylic acid Boc-L-pyroglutamic acid benzyl ester N-Boc-cis-4-cyano-L-proline methyl ester